Details of the Drug Combinations

General Information of This Drug (ID: DM6T2J3)

• Drug Name: Neostigmine (DM6T2J3)
• Synonyms: Eustigmin; Eustigmine; Intrastigmina; Juvastigmin; Neostigmin; Neostigminum; Prostigmin; Prostigmine; Prozerin; Sulfonatooxymethane; Synstigmin; Syntostigmine; Vagostigmin; Vagostigmine; Neostigmine [BAN]; Neostigmine omega; M-Trimethylammoniumphenyldimethylcarbamate; Neostigmine (BAN); Prostigmin (TN); Vagostigmin (TN); [3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium bromide; Ammonium, (m-hydroxyphenyl)trimethyl-, dimethylcarbamate (ester); Benzenaminium, 3-(((dimethylamino)carbonyl)oxy)-N,N,N-trimethyl-(9CI); (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate; (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate (ester); 3-Trimethylammoniumphenyl N,N-dimethylcarbamate; 3-[(dimethylcarbamoyl)oxy]-N,N,N-trimethylanilinium; 3-{[(dimethylamino)carbonyl]oxy}-N,N,N-trimethylanilinium

Indication

Myasthenia gravis; ICD 11: 8C6Y; Status: Approved [1]; Urinary retention; ICD 11: MF50.3; Status: Approved [2]

• Therapeutic Class: Parasympathomimetics
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

9 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Atracurium + Neostigmine	DC0LMK7	Atracurium	Robot-Assisted Laparoscopic Radical Prostatectomy	[3]
Glycopyrrolate + Neostigmine	DCJMR2I	Glycopyrrolate	Surgical Procedures, Elective	[4]
Glycopyrrolate + Neostigmine	DCO1DM0	Glycopyrrolate	Gastrointestinal Dysfunction	[5]
Neostigmine + Rocuronium	DCH0D1S	Rocuronium	Anesthesia	[6]
Glycopyrrolate + Neostigmine	DC0I7J9	Glycopyrrolate	Anesthesia, General	[7]
Glycopyrrolate + Neostigmine	DCX75WN	Glycopyrrolate	Anesthesia, General	[7]
Glycopyrrolate + Neostigmine	DCOIW4S	Glycopyrrolate	Airway Reflexes, Protective	[8]
Glycopyrrolate + Neostigmine	DCNJP9A	Glycopyrrolate	Surgery	[9]
Neostigmine + Rocuronium	DCGD423	Rocuronium	Cirrhosis and Chronic Liver Disease	[10]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Neostigmine FDA Label
• [3] ClinicalTrials.gov (NCT02109133) The Impacts of Surgical Visibility Through Deep Neuromuscular Blockade on Intraocular Pressure in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy
• [4] ClinicalTrials.gov (NCT01479764) Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981)
• [5] ClinicalTrials.gov (NCT02574611) Use of High Resolution Colonic Manometry in Studying Motility
• [6] ClinicalTrials.gov (NCT00675792) Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774)
• [7] ClinicalTrials.gov (NCT00473694) Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025)
• [8] ClinicalTrials.gov (NCT01199237) Impact of Anesthetic Choice (Sevoflurane Versus Desflurane) on Airway Reflex Recovery in the Context of Antagonized Neuromuscular Block
• [9] ClinicalTrials.gov (NCT03939923) Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery
• [10] ClinicalTrials.gov (NCT02414880) Sugammadex Versus Neostigmine in Patients With Liver Cirrhosis Undergoing Liver Resection